Clinical trials: Solid Cancer
Neoplasms
Master Protocol to Assess the Safety and Antitumor Activity of Genetically Engineered T Cells in NY-ESO-1 and/or LAGE-1a Positive Solid Tumors
This trial will evaluate safety and efficacy of human engineered T-cell therapies, in participants with advanced tumors.
- Trial name
- IGNYTE-ESO (NCT03967223)
- Testing
- Letetresgene autoleucel (lete-cel, GSK3377794), Fludarabine, Cyclophosphamide
- Where
- 38 sites in United States, Canada and 5 more
- Volunteers
- 103 people
- Sponsor
- USWM CT, LLC
Hematologic Malignancy, Hematologic Non Malignancy
Using of Virtual Reality to Relieve Procedural Pain in Pediatric Oncology.
Medical procedures can be a very frightening experience for children. It is known that children who received painful medical procedures can develop a higher sensitivity of pain during their following experiences.
- Conditions
- Hematologic Malignancy, Hematologic Non Malignancy, Solid Tumor, Childhood, Child, Only
- Trial name
- VIRTUOSO (NCT05042479)
- Testing
- Usual distraction and pain prevention techniques., Virtual reality, Choice between usual distraction or virtual reality
- Where
- France
- Volunteers
- 34 people
- Sponsor
- Nantes University Hospital
Refractory Solid Tumors, Leukemia
Phase I Study of Bevacizumab and Sorafenib Combined With Low Dose Cyclophosphamide in Patients With Refractory Solid Tumors and Leukemia
Phase I Study of Bevacizumab and Sorafenib Combined with Low Dose Cyclophosphamide in Patients with Refractory Solid Tumors and Leukemia.
- Trial name
- NCT00665990
- Testing
- Bevacizumab, Sorafenib, Cyclophosphamide
- Where
- United States
- Volunteers
- 49 people
- Sponsor
- St. Jude Children's Research Hospital
Solid Tumors
A Phase I Trial of ZIO-101 in Solid Tumors
A Phase I Trial of ZIO-101 (Darinaparsin) in Solid Tumors
- Trial name
- NCT00591396
- Testing
- ZIO-101 (Darinaparsin)
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Alaunos Therapeutics
Malignant Neoplasm
A Study of Ifinatamab Deruxtecan in Pediatric Participants With Relapsed or Refractory Solid Tumors (MK-9999-01D/LIGHTBEAM-U01)
Researchers are looking for new ways to treat children with relapsed or refractory solid tumors: Relapsed means the cancer came back after treatment Refractory means the cancer did not respond (get smaller or go away) to…
- Trial name
- NCT07630974
- Testing
- Ifinatamab Deruxtecan
- Where
- 35 sites in United States, Australia and 11 more
- Volunteers
- 134 people
- Sponsor
- Merck Sharp & Dohme LLC
Cancer, Solid Tumors
Collection of Pharmacokinetic Samples From People With Unanticipated Response, Significant Toxicity or Concern of Future Toxicity
Background: Certain drugs - even when they are meant to help people - cause side effects. These are unwanted effects of the drug. There are many reasons why a drug might cause side effects in one person and not in another.
- Conditions
- Cancer, Solid Tumors, Neoplasm
- Trial name
- NCT02154022
- Where
- United States
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- National Cancer Institute (NCI)
Hematopoietic and Lymphoid Cell Neoplasm, Malignant Solid Neoplasm
Collection of Outcomes Data for Pregnant Patients With Cancer
This study collects treatment and outcomes information on pregnant patients who are or were pregnant with cancer. Gathering and storing health information on pregnant patients with cancer, may provide data for future research…
- Trial name
- NCT00507572
- Testing
- Medical Chart Review
- Where
- United States
- Volunteers
- 313 people
- Sponsor
- M.D. Anderson Cancer Center
Liver Cancer, Advanced Cancer
HAI Irinotecan + IV Bevacizumab, Bevacizumab & Oxaliplatin or Bevacizumab & Cetuximab in Advanced Cancers Metastatic to Liver
The goal of this clinical research study is to learn the highest tolerable dose of irinotecan that can be given directly into the liver, in combination with other drugs given by vein.
- Trial name
- NCT00980239
- Testing
- Irinotecan, Bevacizumab, Oxaliplatin
- Where
- United States
- Volunteers
- 115 people
- Sponsor
- M.D. Anderson Cancer Center
Childhood Hematopoietic and Lymphatic System Neoplasm, Childhood Malignant Solid Neoplasm
Attention Bias Modification for the Improvement of Anxiety in Adolescent and Young Adult Cancer Survivors
This clinical trial studies how well attention bias modification (ABM) improves anxiety in adolescent and young adult (AYA) cancer survivors.
- Trial name
- NCT06682039
- Testing
- Internet-Based Intervention, Interview, Questionnaire Administration
- Where
- United States
- Volunteers
- 70 people
- Sponsor
- Fred Hutchinson Cancer Center
Lymphoma, Myeloma
Allo Non-Myeloablative SCT Utilizing Mis-Matched Family Member Stem Cells Purged Using Campath
Allogeneic transplantation is used to treat many malignant and non-malignant diseases, though the potential toxicities of the procedure remain high.
- Conditions
- Lymphoma, Myeloma, Leukemia, Myelodysplasia
- Trial name
- NCT00580034
- Testing
- Campath Purged Non-myeloablative ASCT, Donor Apheresis
- Where
- United States
- Volunteers
- 176 people
- Sponsor
- David Rizzieri, MD
Unspecified Adult Solid Tumor, Protocol Specific, Unspecified Childhood Solid Tumor, Protocol Specific
Education Intervention in Encouraging Health Providers to Talk With Cancer Patients About the Use of Complementary and Alternative Medicine
RATIONALE: Educating health providers on talking with cancer patients about complementary and alternative medicine (CAM) may help encourage health providers to talk more often with cancer patients about the use of CAM.
- Trial name
- NCT00608933
- Testing
- educational intervention, questionnaire administration
- Where
- 2 sites in United States
- Volunteers
- 1,356 people
- Sponsor
- M.D. Anderson Cancer Center
Cholangiocarcinoma, Neuroblastoma
The Adoptive Immunotherapy for Solid Tumors Using Modified Autologous CIK Cells
Cytokine-induced killer (CIK) cells exhibit high proliferation rate and cytotoxic activity in vitro. The major effector cells are the CD3+CD56+ subset.
- Trial name
- NCT01868490
- Testing
- cytokine induced killer cells
- Where
- 2 sites in Thailand
- Volunteers
- 20 people
- Sponsor
- Siriraj Hospital
Bladder Carcinoma, Breast Cancer
T Cell Receptor-transduced T Cells Targeting NY-ESO-1 for Treatment of Patients With NY-ESO-1- Expressing Malignancies
Background: Autologous T cells engineered to express a T cell receptor (TCR) targeting NY-ESO-1 will be infused back to patients with NY-ESO-1- expressing malignancies.
- Conditions
- Bladder Carcinoma, Breast Cancer, Esophagus Carcinoma, Lung Cancer
- Trial name
- NCT02457650
- Testing
- Cyclophosphamide, Fludarabine, Anti-NY ESO-1 TCR-transduced T cells
- Where
- China
- Volunteers
- 36 people
- Sponsor
- Shenzhen Second People's Hospital
Advanced Malignant Solid Neoplasm, Recurrent Childhood Ependymoma
Palbociclib in Treating Patients With Relapsed or Refractory Rb Positive Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Activating Alterations in Cell Cycle Genes (A Pediatric MATCH Treatment Trial)
This phase II Pediatric MATCH trial studies how well palbociclib works in treating patients with Rb positive solid tumors, non-Hodgkin lymphoma, or histiocytic disorders with activating alterations (mutations) in cell cycle genes…
- Conditions
- Advanced Malignant Solid Neoplasm, Recurrent Childhood Ependymoma, Recurrent Ewing Sarcoma, Recurrent Glioma
- Trial name
- NCT03526250
- Testing
- Laboratory Biomarker Analysis, Palbociclib, Pharmacological Study
- Where
- 117 sites in United States, Puerto Rico
- Volunteers
- 23 people
- Sponsor
- National Cancer Institute (NCI)
Solid Tumor Cancer, Medulloblastoma
Study in Children and Adolescents of 177Lu-DOTATATE (Lutathera®) Combined With the PARP Inhibitor Olaparib for the Treatment of Recurrent or Relapsed Solid Tumours Expressing Somatostatin Receptor (SSTR) (LuPARPed).
Study in children and adolescents of 177Lu DOTATATE (Lutathera®) combined with the PARP inhibitor olaparib for treatment of recurrent or relapsed solid tumours expressing somatostatin receptors (SSTR) (LuPARPed)
- Conditions
- Solid Tumor Cancer, Medulloblastoma, High Risk Neuroblastoma, High Grade Gliomas
- Trial name
- LUPARPED (NCT06607692)
- Testing
- Olaparib; 177Lu-DOTATATE
- Where
- Spain
- Volunteers
- 25 people
- Sponsor
- Fundación de investigación HM
Solid Tumors
Biomarkers for Prediction of Tumor Response to Radiotherapy
This study aims to explore potential biomarkers for prediction of therapeutic outcomes in patients with solid tumors after radiotherapy
- Trial name
- NCT03744819
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Chuangzhen Chen
Chemotherapeutic Agent Toxicity, Sarcoma
CYP3A5 Gene as a Risk Factor for Kidney Damage in Young Patients With Cancer Treated With Ifosfamide
RATIONALE: Studying the genes expressed in samples of blood from young patients with cancer treated with ifosfamide may help doctors identify risk factors for kidney damage.
- Conditions
- Chemotherapeutic Agent Toxicity, Sarcoma, Unspecified Childhood Solid Tumor, Protocol Specific
- Trial name
- NCT00514345
- Testing
- gene expression analysis, polymorphism analysis, management of therapy complications
- Where
- 21 sites in Ireland, United Kingdom
- Volunteers
- 300 people
- Sponsor
- Children's Cancer and Leukaemia Group
Neuroblastoma, Sarcoma
Donor Stem Cell Transplant in Treating Young Patients With Relapsed or Refractory Solid Tumors
RATIONALE: A peripheral stem cell, bone marrow, or umbilical cord blood transplant may be able to replace blood-forming cells that were destroyed by chemotherapy and radiation therapy.
- Conditions
- Neuroblastoma, Sarcoma, Unspecified Childhood Solid Tumor, Protocol Specific
- Trial name
- NCT00112645
- Testing
- anti-thymocyte globulin, busulfan, cyclosporine
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Milton S. Hershey Medical Center
Carcinoma In Situ, Hematopoietic and Lymphatic System Neoplasm
Web-Based Physical Activity Intervention in Improving Long Term Health in Children and Adolescents With Cancer
This randomized clinical phase III trial studies how well web-based physical activity intervention works in improving long term health in children and adolescents with cancer.
- Conditions
- Carcinoma In Situ, Hematopoietic and Lymphatic System Neoplasm, Malignant Solid Neoplasm
- Trial name
- NCT03223753
- Testing
- Educational Intervention, Internet-Based Intervention, Laboratory Biomarker Analysis
- Where
- 118 sites in United States, Canada
- Volunteers
- 299 people
- Sponsor
- Children's Oncology Group
Acute Leukemias of Ambiguous Lineage, Acute Undifferentiated Leukemia
Obatoclax Mesylate, Vincristine Sulfate, Doxorubicin Hydrochloride, and Dexrazoxane Hydrochloride in Treating Young Patients With Relapsed or Refractory Solid Tumors, Lymphoma, or Leukemia
This phase I trial is studying the side effects and best dose of obatoclax mesylate when given together with vincristine sulfate, doxorubicin hydrochloride, and dexrazoxane hydrochloride in treating young patients with relapsed…
- Conditions
- Acute Leukemias of Ambiguous Lineage, Acute Undifferentiated Leukemia, Angioimmunoblastic T-cell Lymphoma, Blastic Phase Chronic Myelogenous Leukemia
- Trial name
- NCT00933985
- Testing
- dexrazoxane hydrochloride, doxorubicin hydrochloride, obatoclax mesylate
- Where
- 20 sites in United States, Canada
- Volunteers
- 22 people
- Sponsor
- National Cancer Institute (NCI)